Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH 2021 | The use of post-transplant cyclophosphamide

Anna Sureda • 23 Sep 2021
IACH 2021
General Cyclophosphamide

Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Barcelona, Spain, discusses the use of post-transplant cyclophosphamide. Cyclophosphamide is given after allogeneic stem cell transplantation as a graft-versus-host disease (GvHD) prophylaxis platform as it is very effective in the context of haploidentical transplants. For this reason, it has made the process of allogeneic stem cell transplantation accessible to almost all patients. Dr Sureda predicts that in the future, cyclophosphamide will be used more broadly. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.

More from Anna Sureda

1:54
Looking forward to the 50th Annual Meeting of the EBMT
Anna Sureda • 7 Mar 2024
3:32
The risk of secondary malignancies following CAR T-cell therapy: current evidence
Anna Sureda • 7 Mar 2024
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:16
The success of the EBMT-EHA 6th European CAR T-cell Meeting
Anna Sureda • 7 Mar 2024

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals